Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Blood (2024) 143 (11): 1006–1017.

https://doi.org/10.1182/blood.2023020515

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

Greiner Georg, MD PhD, Michael Gurbisz, MSc, Franz Ratzinger, MD, Nadine Witzeneder, MSc, Svenja-Verena Class, Ingrid Simonitsch-Klupp, MD, Harald Esterbauer, MD PhD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, Leonhard Muellauer, MD PhD, Peter Valent, Gregor Hoermann

Blood (2018) 132 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2018-99-116492

Published: 2018

Journal Articles

Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis

Greiner Georg, MD PhD, Michael Gurbisz, MSc, Franz Ratzinger, MD, Nadine Witzeneder, MSc, Ingrid Simonitsch-Klupp, MD, Gerlinde Mitterbauer-Hohendanner, MD, Matthias Mayerhofer, MD, Leonhard Muellauer, MD PhD, Wolfgang R. Sperr, MD, Peter Valent, MD, Gregor Hoermann, MD

Blood (2017) 130 (Supplement 1): 2927.

https://doi.org/10.1182/blood.V130.Suppl_1.2927.2927

Published: 2017

Journal Articles

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

Georg Greiner, Nadine Witzeneder, Angelika Berger, Klaus Schmetterer, Gregor Eisenwort, Ana-Iris Schiefer, Simone Roos, Theresia Popow-Kraupp, Leonhard Müllauer, Johannes Zuber, Veronika Sexl, Lukas Kenner, Wolfgang R. Sperr, Peter Valent, Matthias Mayerhofer, Gregor Hoermann

Blood (2017) 129 (3): 371–382.

https://doi.org/10.1182/blood-2016-09-739003

Published: 2017

Includes: Supplemental data

Journal Articles

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

Katharina Blatt, Sabine Cerny-Reiterer, Juliana Schwaab, Karl Sotlar, Gregor Eisenwort, Gabriele Stefanzl, Gregor Hoermann, Matthias Mayerhofer, Mathias Schneeweiss, Sylvia Knapp, Thomas Rülicke, Emir Hadzijusufovic, Karin Bauer, Dubravka Smiljkovic, Michael Willmann, Andreas Reiter, Hans-Peter Horny, Peter Valent

Blood (2015) 126 (26): 2832–2841.

https://doi.org/10.1182/blood-2015-03-637728

Published: 2015

Includes: Supplemental data

Journal Articles

CCL-2 Is a KIT D816V-Dependent Modulator of Bone Marrow Remodeling and Microenvironmental Alterations in Systemic Mastocytosis

Georg Greiner, MD, Nadine Witzeneder, Klaus Schmetterer, MD PhD, Theresia Popow-Kraupp, MD, Wolfgang R Sperr, MD, Peter Valent, MD, Matthias Mayerhofer, MD, Gregor Hoermann, MD PhD

Blood (2015) 126 (23): 1635.

https://doi.org/10.1182/blood.V126.23.1635.1635

Published: 2015

Journal Articles

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Harald Herrmann, Irina Sadovnik, Sabine Cerny-Reiterer, Thomas Rülicke, Gabriele Stefanzl, Michael Willmann, Gregor Hoermann, Martin Bilban, Katharina Blatt, Susanne Herndlhofer, Matthias Mayerhofer, Berthold Streubel, Wolfgang R. Sperr, Tessa L. Holyoake, Christine Mannhalter, Peter Valent

Blood (2014) 123 (25): 3951–3962.

https://doi.org/10.1182/blood-2013-10-536078

Published: 2014

Includes: Supplemental data

Journal Articles

Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis

Katharina Blatt, MSc, Ph.D., Sabine Cerny-Reiterer, D.V.M, Karl Sotlar, M.D., Schwaab Juliana, M.D., Gregor Hoermann, M.D., Ph.D., Matthias Mayerhofer, M.D., Emir Hadzijusufovic, DVM, Michael Willmann, D.V.M., Andreas Reiter, MD, Hans-Peter Horny, MD, Peter Valent

Blood (2013) 122 (21): 3773.

https://doi.org/10.1182/blood.V122.21.3773.3773

Published: 2013

Journal Articles

Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis.

Gregor Hoermann, M.D., Ph.D., Katharina Blatt, MSc, Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Leonhard Müllauer, M.D., Peter Valent, MD, Matthias Mayerhofer, M.D.

Blood (2012) 120 (21): 2866.

https://doi.org/10.1182/blood.V120.21.2866.2866

Published: 2012

Journal Articles

The Leukemic Stem Cell (LSC) in Ph + CML Is a CD34 + /CD38 − /Lin − Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

Harald Herrmann, M.D., Irina Sadovnik, M.Sc., Sabine Cerny-Reiterer, D.V.M., Katharina Blatt, M.Sc., Viviane Ghanim, M.D., Susanne Herndlhofer, Gregor Hoermann, M.D., Thomas Rülicke, D.V.M., Michael Willmann, D.V.M., Gerlinde Mitterbauer-Hohendanner, M.D., Matthias Mayerhofer, M.D., Wolfgang R. Sperr, M.D., Peter Valent, M.D.

Blood (2011) 118 (21): 961.

https://doi.org/10.1182/blood.V118.21.961.961

Published: 2011

Journal Articles

KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

Karoline V. Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, Gregor Hörmann, Uwe Rix, Keiryn L. Bennett, Emir Hadzijusufovic, Renata A. Meyer, Winfried F. Pickl, Jason Gotlib, Hans-Peter Horny, Andreas Reiter, Gerlinde Mitterbauer-Hohendanner, Giulio Superti-Furga, Peter Valent

Blood (2011) 118 (7): 1885–1898.

https://doi.org/10.1182/blood-2010-06-289959

Published: 2011

Includes: Supplemental data

Journal Articles

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

Wolfgang Warsch, Karoline Kollmann, Eva Eckelhart, Sabine Fajmann, Sabine Cerny-Reiterer, Andrea Hölbl, Karoline V. Gleixner, Michael Dworzak, Matthias Mayerhofer, Gregor Hoermann, Harald Herrmann, Christian Sillaber, Gerda Egger, Peter Valent, Richard Moriggl, Veronika Sexl

Blood (2011) 117 (12): 3409–3420.

https://doi.org/10.1182/blood-2009-10-248211

Published: 2011

Includes: Supplemental data

Journal Articles

Identification of Basophils as Source of Hepatocyte Growth Factor (HGF) In CML: a Potential Trigger of Disease Acceleration.

Sabine Cerny-Reiterer, DVM, Karl J. Aichberger, MD, Harald Herrmann, MD, Gregor Hoermann, MD, Barbara Peter, MVM, Leonhard Muellauer, MD, Matthias Mayerhofer, MD, Peter Valent, MD

Blood (2010) 116 (21): 1202.

https://doi.org/10.1182/blood.V116.21.1202.1202

Published: 2010

Journal Articles

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Karl J. Aichberger, Karoline V. Gleixner, Irina Mirkina, Sabine Cerny-Reiterer, Barbara Peter, Veronika Ferenc, Michael Kneidinger, Christian Baumgartner, Matthias Mayerhofer, Alexander Gruze, Winfried F. Pickl, Christian Sillaber, Peter Valent

Blood (2009) 114 (26): 5342–5351.

https://doi.org/10.1182/blood-2008-08-175190

Published: 2009

Journal Articles

Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells.

Karoline Veronika Gleixner, MD, Matthias Mayerhofer, MD, Gregor Hörmann, Karina Schuch, Sabine Cerny-Reiterer, MD, Barbara Peter, M.V.M, Harald Herrmann, MD, Winfried F. Pickl, MD, Christian Sillaber, Peter Valent, MD

Blood (2009) 114 (22): 1717.

https://doi.org/10.1182/blood.V114.22.1717.1717

Published: 2009

Journal Articles

Identification of Oncostatin M as a Novel KIT D816V-Dependent Cytokine in Neoplastic Human Mast Cells.

Gregor Hoermann, MD, Sabine Cerny-Reiterer, MD, Andrea Perne, MD, Miriam Klauser, Leonhard Muellauer, MD, Peter Valent, MD, Matthias Mayerhofer, MD

Blood (2009) 114 (22): 213.

https://doi.org/10.1182/blood.V114.22.213.213

Published: 2009

Journal Articles

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Renata A. Meyer, MD, Harald Herrmann, MD, Karoline V. Gleixner, MD, Alexander Gruze, Sabine Cerny-Reiterer, MD, Rainer Hubmann, PhD, Medhat Shehata, MD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, MD, Winfried F. Pickl, MD, Junia V. Melo, PhD, Gahininath Y. Bharate, Ulrich Jäger, MD, Hiroshi Maeda, MD, PhD, Peter Valent, MD

Blood (2008) 112 (11): 1616.

https://doi.org/10.1182/blood.V112.11.1616.1616

Published: 2008

Journal Articles

Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib

Matthias Mayerhofer, Karoline V. Gleixner, Julia Mayerhofer, Gregor Hoermann, Eva Jaeger, Karl J. Aichberger, Rene G. Ott, Khaled Greish, Hideaki Nakamura, Sophia Derdak, Puchit Samorapoompichit, Winfried F. Pickl, Veronika Sexl, Harald Esterbauer, Ilse Schwarzinger, Christian Sillaber, Hiroshi Maeda, Peter Valent

Blood (2008) 111 (4): 2200–2210.

https://doi.org/10.1182/blood-2006-11-055723

Published: 2008

Journal Articles

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

Karoline V. Gleixner, MD, Matthias Mayerhofer, M.D., Uwe Rix, Ph.D., Gregor Hoermann, Alexander Gruze, Maria-Theresa Krauth, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Giulio Superti-Furga, Ph.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1541.

https://doi.org/10.1182/blood.V110.11.1541.1541

Published: 2007

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Veronika Ferenc, MD, Karoline V. Gleixner, M.D., Alexander Gruze, M.D., Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 3554.

https://doi.org/10.1182/blood.V110.11.3554.3554

Published: 2007

NARROW

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis

CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

CCL-2 Is a KIT D816V-Dependent Modulator of Bone Marrow Remodeling and Microenvironmental Alterations in Systemic Mastocytosis

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis

Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis.

The Leukemic Stem Cell (LSC) in Ph + CML Is a CD34 + /CD38 − /Lin − Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α

KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

Identification of Basophils as Source of Hepatocyte Growth Factor (HGF) In CML: a Potential Trigger of Disease Acceleration.

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells.

Identification of Oncostatin M as a Novel KIT D816V-Dependent Cytokine in Neoplastic Human Mast Cells.

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only